Results 81 to 90 of about 1,403,082 (309)
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases
The Journal of Clinical Investigation, 2023 BACKGROUND We previously demonstrated the safety of stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) in patients with advanced solid tumors.Mark C. Korpics, Benjamin E. Onderdonk, Rebekah E. Dadey, Jared H. Hara, Lilit Karapetyan, Yuanyuan Zha, Theodore G. Karrison, Adam C. Olson, Gini F. Fleming, Ralph R. Weichselbaum, Riyue Bao, Steven J. Chmura, Jason J. Luke +12 moredoaj +1 more sourceGenomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text
Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton +19 morewiley +1 more sourceA nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun +13 morewiley +1 more sourceMetronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer [PDF]
, 2018 Lung cancer is the leading cause of death worldwide. The treatment choice for advanced stage of lung cancer may depend on histotype, performance status (PS), age, and comorbidities. In the present study, we focused on the effect of metronomic vinorelbine Bruno, P, D'Ascanio, M, Fiorentino, C, Grieco, A, Mancini, R, Pezzuto, A, Ricci, A, Sposato, B +7 morecore +1 more sourceEvaluating Treatment Plan Modifications from Surgeons’ Initial Recommendations to Multidisciplinary Tumor Board Consensus for Cancer Care in a Resource-Limited Setting
Current OncologyMultidisciplinary tumor boards (MTBs) are essential for optimizing cancer care through collaborative decision-making. However, the concordance between initial surgeons’ recommendations and MTB outcomes, particularly in resource-limited settings, remains ...Sajida Qureshi, Waqas Ahmad Abbasi, Hira Abdul Jalil, Raheel Ahmed, Mubashir Iqbal, Hanieya Saiyed, Hira Fatima Waseem, Najeeb Naimatullah, Syed Rashidul Amin, Muhammad Saeed Quraishy +9 moredoaj +1 more sourceUnraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández +12 morewiley +1 more sourceBRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers [PDF]
, 2016 Background: The K3326X variant in BRCA2 (BRCA2*c.9976A>T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer.Agnarsson, Bjarni A., Aittomäki, Kristiina, Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Bandera, Elisa V., Banerjee, Susana, Barile, Monica, Barrowdale, Daniel, Beckman, Matthias W., Beeghly-Fadiel, Alicia, Benitez, Javier, Berchuck, Andrew, Bjorge, Line, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Stig E., Bolla, Manjeet K., Borg, Ake, Borresen-Dale, Anne-Lise, Brauch, Hiltrud, Brenner, Hermann, Broeks, Annegien, Bruinsma, Fiona, Brunet, Joan, Brüning, Thomas, Burwinkel, Barbara, Butterbach, Katja, Butzow, Ralf, Buys, Saundra S., Cai, Hui, Campbell, Ian G., Cannioto, Rikki, Castillo, Danielle, Chan, Salina B., Chang-Claude, Jenny, Chenevix-Trench, Georgia, Claes, Kathleen B. M., Collavoli, Anita, Cook, Linda S., Couch, Fergus J., Cox, Angela, Cramer, Daniel, Cross, Simon S., Cunningham, Julie M., Czene, Kamila, Daly, Mary B., Damiola, Francesca, Darabi, Hatef, de la Hoya, Miguel, Dennis, Joe, Devilee, Peter, Diez, Orland, Ding, Yuan Chun, Doherty, Jennifer A., Domchek, Susan M., Dorfling, Cecilia M., Dunning, Alison M., Dörk, Thilo, Easton, Douglas F., Eccles, Diana M., Ellis, Steve, Eunjung, Lee, Fasching, Peter A., Feng, Bingjian, Figueroa, Jonine, Flesch-Janys, Dieter, Fletcher, Olivia, Flyger, Henrik, Foretova, Lenka, Fostira, Florentia, Friedman, Eitan, Frost, Debra, Ganz, Patricia N., Gao, Yu-Tang, Garber, Judy, García-Closas, Montserrat, Gayther, Simon, Gerdes, Anne-Marie, Giles, Graham G., Glasspool, Rosalind, Godwin, Andrew K., Goldberg, Mark S., Goldgar, David E., González-Neira, Anna, Goode, Ellen L., Goodman, Marc T., Greene, Mark H., Gronwald, Jacek, Guénel, Pascal, Hahnen, Eric, Haiman, Christopher A., Hall, Per, Hallberg, Emily, Hamann, Ute, Hansen, Thomas V. O., Hart, Steven N., Healey, Sue, Heitz, Florian, Henderson, Brian E., Henriksson, Karin, Hildebrant, Michelle A. T., Hogdall, Claus, Hogdall, Estrid, Hogervorst, Frans B. L., Hopper, John L., Hosono, Satoyo, Hulick, Peter J., Imyanitov, Evgeny N., Isaacs, Claudine, Jakubowska, Anna, James, Paul A., Janavicius, Ramunas, Jensen, Allen, John, Esther M., Johnson, Nichola, Jones, Michael, Kabisch, Maria, Karlan, Beth Y., Khan, Sofia, Kiemeney, Lambertus A., Kjaer, Susanne K., Knight, Julia A., Konstantopoulou, Irene, Koppert, Linetta B., Kosma, Veli-Matti, Kristensen, Vessela, Kupryjanczyk, Jolanta, Kwong, Ava, Laitman, Yael, Lambrechts, Diether, Lazaro, Conxi, Le, Nhu, Lester, Jenny, Levine, Douglas, Li, Jingmei, Liang, Dong, Lindblom, Annika, Loud, Jennifer T., Lu, Karen H., Lubinski, Jan, Mai, Phuong L., Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Marme, Frederik, Massuger, Leon F. A. G., Matsuo, Keitaro, Maugard, Christine, Mazoyer, Sylvie, McGuffog, Lesley, McNeish, Iain, Meeks, Huong D., Meindl, Alfons, Menon, Usha, Michailidou, Kyriaki, Milne, Roger L., Modugno, Francesmary, Moes-Sosnowska, Joanna, Montagna, Marco, Monteiro, Alvaro N. A., Moysich, Kirsten B., Narod, Steven, Nathanson, Katherine L., Ness, Roberta, Neuhausen, Susan L., Nevanlinna, Heli, Neven, Patrick, Nussbaum, Robert L., Offit, Kenneth, Olah, Edith, Oliani, Cristina, Olopade, Olufunmilayo I., Olson, Janet E., Olson, Sara H., Osorio, Ana, Park, Sue K., Pasini, Barbara J., Pearce, Leigh, Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Pejovic, Tanja, Pelttari, Liisa M., Peterlongo, Paolo, Pharoah, Paul D. P., Phelan, Catherine M., Piedmonte, Marion, Poole, Elizabeth M., Pylkäs, Katri, Radice, Paolo, Ramus, Susan J., Rantala, Johanna, Rappaport-Feurhauser, Christine, Rennert, Gad, Riboli, Elio, Risch, Harvey, Robson, Mark, Rossing, Mary Anne, Rudolph, Anja, Salvesen, Helga B., Sawyer, Elinor J., Schildkraut, Joellen, Schmidt, Marjanka K., Schoemaker, Minouk J., Segura, Pedro Perez, Senter, Leigha, Shah, Mitul, Shimelis, Hermela, Siddiquil, Nadeem, Sieh, Weiva, Simard, Jacques, Singer, Christian F., Sinilnikova, Olga M., Slager, Susan, Song, Honglin, Soucy, Penny, Southey, Melissa C., Spurdle, Amanda B., Stoppa-Lyonnet, Dominique, Swerdlow, Anthony, Teixeira, Manuel R., Teo, Soo Hwang, Terry, Kathryn L., Terry, Mary Beth, Tesoriero, Andrea, Thomassen, Mads, Thompson, Pamela J., Tihomirova, Laima, Tischkowitz, Marc, Tollenaar, Robert A. E. M., Tomlinson, Ian, Torres, Diana, Truong, Thérèse, Tucker, Kathy, Tung, Nadine, Tworoger, Shelley S., van der Ouweland, Ans M. W., Van Maerken, Tom, van Rensburg, Elizabeth J., Varon-Mateeva, Raymonda, Viel, Alessandra, Wang, Qin, Wappenschmidt, Barbara, Weitzel, Jeffrey N., Wentzensen, Nicolas, Whittermore, Alice S., Winqvist, Robert, Woo, Yin Ling, Wu, Anna, Yoon, Sook-Yee, Zheng, Wei, Öfverholm, Anna +252 morecore +1 more sourcePhase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer
The Journal of Clinical Investigation, 2022 BACKGROUND Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has achieved remarkable clinical efficacy in metastatic cancers such as melanoma and cervical cancer (CC).He Huang, Cai-ping Nie, Xiu-feng Liu, Bin Song, Jian-hui Yue, Jing-xiao Xu, Jia He, Kui Li, Yan-ling Feng, Ting Wan, Min Zheng, Yan-Na Zhang, Wei-Jun Ye, Jun-Dong Li, Yan-Fang Li, Jun-yun Li, Xin-Ping Cao, Zhi-min Liu, Xiao-shi Zhang, Qing Liu, Xi Zhang, Ji-Hong Liu, Jiang Li +22 moredoaj +1 more source
